165 related articles for article (PubMed ID: 30170240)
41. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
42. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
Godi A; Bissett SL; Miller E; Beddows S
J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
[TBL] [Abstract][Full Text] [Related]
43. Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes.
Conway MJ; Cruz L; Alam S; Christensen ND; Meyers C
PLoS One; 2011 Feb; 6(2):e16405. PubMed ID: 21346798
[TBL] [Abstract][Full Text] [Related]
44. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
Kulski JK; Sadleir JW; Kelsall SR; Cicchini MS; Shellam G; Peng SW; Qi YM; Galloway DA; Zhou J; Frazer IH
Virology; 1998 Apr; 243(2):275-82. PubMed ID: 9568027
[TBL] [Abstract][Full Text] [Related]
45. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
[TBL] [Abstract][Full Text] [Related]
46. Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies.
Zhang Y; He Y; Li L; Liang S; Yan M; Ren D; Yang Z; Zhao W; Miao L; Zhang H; Liu Y
Diagn Pathol; 2018 Aug; 13(1):55. PubMed ID: 30115088
[TBL] [Abstract][Full Text] [Related]
47. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
48. Insights into the role and function of L2, the minor capsid protein of papillomaviruses.
Pereira R; Hitzeroth II; Rybicki EP
Arch Virol; 2009; 154(2):187-97. PubMed ID: 19169853
[TBL] [Abstract][Full Text] [Related]
49. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
[TBL] [Abstract][Full Text] [Related]
50. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
51. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
52. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions.
Liu WJ; Gissmann L; Sun XY; Kanjanahaluethai A; Müller M; Doorbar J; Zhou J
Virology; 1997 Jan; 227(2):474-83. PubMed ID: 9018146
[TBL] [Abstract][Full Text] [Related]
53. Efficient Inhibition of Human Papillomavirus Infection by L2 Minor Capsid-Derived Lipopeptide.
Yan H; Foo SS; Chen W; Yoo JS; Shin WJ; Wu C; Jung JU
mBio; 2019 Aug; 10(4):. PubMed ID: 31387913
[TBL] [Abstract][Full Text] [Related]
54. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
Motavalli Khiavi F; Arashkia A; Golkar M; Nasimi M; Roohvand F; Azadmanesh K
J Immunol Res; 2018; 2018():9464186. PubMed ID: 29854852
[No Abstract] [Full Text] [Related]
55. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.
Carter JJ; Wipf GC; Benki SF; Christensen ND; Galloway DA
J Virol; 2003 Nov; 77(21):11625-32. PubMed ID: 14557648
[TBL] [Abstract][Full Text] [Related]
56. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
57. The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae.
Kwag HL; Kim HJ; Chang DY; Kim HJ
J Microbiol; 2012 Oct; 50(5):813-20. PubMed ID: 23124750
[TBL] [Abstract][Full Text] [Related]
58. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
59. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
[TBL] [Abstract][Full Text] [Related]
60. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
Day PM; Gambhira R; Roden RB; Lowy DR; Schiller JT
J Virol; 2008 May; 82(9):4638-46. PubMed ID: 18305047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]